MDT-AP-0370
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 77.03999999999999
- os_event
- false
- age_years
- 3
- sex
- M
- new_clusters
- C2
- umap1_2d
- 2.191024745
- umap2_2d
- -0.053595811
- umap1_3d
- -0.916495336
- umap2_3d
- -1.957661422
- umap3_3d
- -0.504926323
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.570
- ANGIOGENESIS+0.490
- OXIDATIVE_PHOSPHORYLATION+0.480
- MTORC1_SIGNALING+0.470
- MYC_TARGETS_V1+0.470
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.470
- TNFA_SIGNALING_VIA_NFKB+0.410
- CHOLESTEROL_HOMEOSTASIS+0.370
- UNFOLDED_PROTEIN_RESPONSE+0.370
- ANDROGEN_RESPONSE+0.350
Top 10 suppressed
- MITOTIC_SPINDLE-0.240
- HEDGEHOG_SIGNALING-0.220
- UV_RESPONSE_DN-0.140
- PI3K_AKT_MTOR_SIGNALING-0.050
- BILE_ACID_METABOLISM-0.030
- APICAL_JUNCTION+0.000
- INTERFERON_GAMMA_RESPONSE+0.000
- PROTEIN_SECRETION+0.000
- NOTCH_SIGNALING+0.010
- INTERFERON_ALPHA_RESPONSE+0.030
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0532 | Med | Medulloblastoma | 0.935 |
| 2 | SRR11296801 | — | — | 0.906 |
| 3 | MDT-AP-2118 | Med | Medulloblastoma | 0.879 |
| 4 | TCGA-G2-A2EO-01A-11R-A180-07 | — | — | 0.879 |
| 5 | MDT-AP-1185 | Med | Medulloblastoma | 0.878 |
| 6 | MDT-AP-2001 | Med | Medulloblastoma | 0.877 |
| 7 | MDT-AP-2506 | Med | Medulloblastoma | 0.875 |
| 8 | SRR13780253 | — | cohortMD1 | 0.873 |
| 9 | X3a5c813b.6c47.49aa.916c.bcddbafdd54b | — | cohortA1 | 0.849 |
| 10 | TCGA-52-7811-01A-11R-2125-07 | — | cohortSQ1 | 0.844 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.570 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.490 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.480 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.470 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.470 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.470 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.410 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.370 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.370 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.350 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.320 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.310 | Inavolisib | — uncovered |
| HYPOXIA | 0.310 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.300 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.280 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.270 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.240 | Idelalisib | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.240 | Idelalisib | — uncovered |